A Phase 1, Open-Label, Multicenter, Dose Escalation Study of mRNA-2752, a Lipid Nanoparticle Encapsulating mRNAs Encoding Human OX40L, IL-23, and IL-36, for Intratumoral Injection Alone and in Combination with Immune Checkpoint Blockade (NCT03739931)
mRNA-2752
This trial is No longer recruiting
Registration number NCT03739931
Program & service
This trial is being run with the Cancer service, and as part of the Medical Oncology program.
Trial phase
Phase 1
Trial participation type
This trial has been designed for the Clinical Research of a Drug.
Principal investigator
Associate Professor Andrew Haydon
More information
To find out more about this clinical trial, please review full details on the ANZCTR website.
View on ANZCTR